Abstract
Background: Among millions of HIV infected individuals in India, few receive HAART as a result of high costs. Generic manufacture of drugs here has led to price reductions of HAART. Generic drugs impact multinational pharmaceutical companies' ability to reclaim their costs of research & development. The World Trade Organization's (WTO) Trade Related Aspects of Intellectual Property Agreement (TRIPS) requires patent protection for pharmaceutical inventions, preventing generic competitors from producing cheaper alternatives. Under certain provisions of TRIPS, Indian pharmaceuticals were able to manufacture low cost generic HAART until now. Recently, the Indian government passed a bill regulating pharmaceuticals to comply with TRIPS. Stoppage of generic drug manufacturing can diminish access to HAART for large numbers of HIV infected people. However, several other barriers can also decrease access to HAART.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Internet Journal of Law, Healthcare and Ethics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
